Introduction
During the spring of 2009, a novel swine-origin influenza A (H1N1) virus (S-OIV) that caused human infections in Mexico, spread first to the United States and Canada, and then spread globally [1] [2] [3] . By August 1, 2010, before WHO Director-General Dr Margaret Chan announced that the H1N1 influenza event had moved into the post-pandemic period, almost every country had reported laboratory-confirmed cases, with over 18 449 total deaths (http://www.who.int/csr/don/2010_08_06/en/ index. html). This was the first influenza pandemic since 1968, and it caused acute respiratory illness and acute lung injury, especially in its severe form. Acute respiratory distress syndrome was reported to be the predominant cause for the reported deaths [4, 5] . Recent media reports npg patients from December 27, 2010 to January 2, 2011 in Beijing and found that 23.08% were infected with S-OIV H1N1 (http://news.xinhuanet.com/politics/2011-01/10/ c_12963482.htm). Altogether, these data suggest that the 2009 H1N1 strain is still circulating in the world. Previous clinical reports indicated that hypercytokinemia is involved in the pathology of severe 2009 pandemic influenza [6] [7] [8] . However, the underlying molecular mechanism is unclear. To elucidate the molecular pathogenesis, an appropriate animal model is needed. Models of the 2009 pandemic influenza have been reported in mice, ferrets, guinea pigs and non-human primates [9] [10] [11] [12] . The selection of an appropriate animal model that accurately reflects the disease and the protective immune response against infection in human has been a major challenge in influenza research. Mice are commonly used as animal models for influenza research because of the convenience of genetic modulation, though they are not ideal for transmission studies [9] . However, currently available mouse models are incapable of emulating human influenza-based disease and the immune responses to the 2009 pandemic influenza [9, 13, 14] . Therefore, we screened several influenza virus strains isolated in China during the 2009 pandemic. We found that an isolate termed A/Beijing/501/2009 (H1N1) (BJ501) caused severe respiratory disease in mice and that it may be appropriate for use in setting up a mouse model for influenza research (Figure 1) .
Results

Mice infected with the Beijing 501 (BJ501) strain of S-OIV H1N1 developed severe acute lung injury
Compared with seasonal influenza, H1N1 and the pandemic 2009 A/California/07/2009 (CA07) isolate, which does not cause mortality in mice at the highest possible virus titers, the BJ501 isolate had a median lethal dose (LD50) at a virus titer of log10 4.2 in 6-to 8-week-old B/C mice ( Figure 1A) . Moreover, 4-week-old B6 mice were found to be more sensitive to the 2009 pandemic influenza infection and to show representative characteristics of the human disease ( Figure 1A ). This result is consistent with the clinical reports that infants and children, infected with influenza are more likely to develop complications than adults [5] . Therefore, 4-week-old B6 mice were used for the influenza model in this report. However, compared with the commonly used mouseadapted influenza A/Puerto Rico/8/34 (PR8) strain, the mortality rate caused by BJ501 was lower ( Figure 1A ). Mouse body weight loss induced by BJ501 infection was as high as 40%, whereas the weight losses caused by seasonal H1N1 and CA07 isolate infections were 10% and 20%, respectively ( Figure 1B) . However, no differences in virus replication were observed among strains ( Figure 1C ). The pathological alterations of mouse lung tissue infected with the 2009 pandemic influenza BJ501 strain were more severe than those in tissue infected with the 2009 pandemic influenza CA07 or seasonal influenza ( Figure 1D ). Lung edema, as defined by the wet-to-dry ratio of the lung tissue, was observed in BJ501 and PR8 infections ( Figure 1E ). These data of acute lung injury are consistent with the clinical reports of 2009 pandemic influenza [15] . Thus, 4-week-old B6 mice infected with the BJ501 isolate, whose hemagglutinin (HA) genome is 99% identical to the 2009 pandemic CA07 strain (Figure 1F) , could potentially be an ideal animal model for severe cases of 2009 pandemic influenza infection in human [16, 17] .
Administration of Oseltamivir at early stages of infection ameliorated acute lung injury
During the 2009 pandemic, no specific therapeutics existed for the treatment of the disease. The commonly applied therapeutics included antiviral (mostly Tamiflu/ Oseltamivir) and corticosteroid treatments [18] . While controversy regarding the drug efficacy of corticosteroids in the treatment of acute respiratory distress syndrome patients infected with 2009 pandemic H1N1 has been reported [19, 20] , the effects of Tamiflu treatment at an early stage of disease-onset are well-established [21] [22] [23] . Using our newly established mouse model, infected with the 2009 pandemic BJ501 strain, we tested the drug efficacy of Oseltamivir. The survival rate of the mice was significantly improved when they were given Oseltamivir during the first 3 days of infection ( Figure 2A) . However, improvement in the survival rate was not significant when the mice were given Oseltamivir after the first 3 days of infection ( Figure 2B ). Acute lung injury, as measured by lung pathology and wet-to-dry weight ratio, was also improved when mice were given Oseltamivir in the early stages of BJ501 infection ( Figure 2C, 2D) . These results were consistent with the reported human clinical data [23] . Therefore, 4-week-old B6 mice, infected with the BJ501 isolate, represent a validated animal model that can be used to evaluate potential therapeutic drugs.
Cytokine responses in patients and mice infected with 2009 H1N1 influenza A virus
Previous clinical reports analyzing sera obtained from 29 patients in Spain and 57 patients in Hong Kong showed that Th-1 and Th-17 hypercytokinemia is an early host response signature in severe cases of 2009 pandemic influenza [6, 8] . However, controversy regarding the role of the Th-17 response was raised by a npg recent study from a Romanian group reporting cytokine responses in 32 patients with severe H1N1 influenza A virus infection [7] . The elevation of IL-17 was observed in neither mild nor acute respiratory distress syndrome cases [7] . In an effort to further clarify this issue, we recruited 37 patients who were PCR positive for the 2009 H1N1 influenza A virus from two hospitals in Beijing.
The characteristics underlying the conditions and outcomes of the 37 patients infected with 2009 influenza A are described in Supplementary information, Table S1 . After excluding patients whose serum samples were collected 8 days after disease-onset, patients under 16 years old and patients who had immune diseases (Supplementary information, Figure S1 ), we profiled 24 cytokines and chemokines from the serum samples of 23 qualified patients ( Figure 3A ). Unlike previous reports, Th-1 hypercytokinemia was not observed in our patient groups compared with healthy individuals [6] ( Figure 3A) . However, IL-17 was elevated in all mild, hospitalized and critical patient groups ( Figure 3A ). Th-17 mediators, including IL-6 and IL-8, and IL-17-responsive cytokines and chemokines, including G-CSF and GM-CSF, were also elevated ( Figure 3A ), suggesting that IL-17 may play an important role in the pathogenesis associated with 2009 pandemic influenza infection. Using the B6 mouse model infected with the BJ501 virus, we profiled 23 mouse cytokines and chemokines from the mouse lung bronchoalveolar lavage fluids (BALFs) ( Figure 3B ). The profile of cytokines and chemokines from infected mice was generally similar to that from patient serum samples in Beijing, indicating that 4-week-old B6 mice infected with the BJ501 isolate could reflect human immune responses to 2009 pandemic influenza infection in the Beijing area. Levels of IL-17, Th-17 mediators, and IL-17-responsive cytokines and chemokines were all elevated in the BALFs of infected mouse lungs ( Figure  3B ). We thus hypothesized that IL-17 might play a critical role in the host response to 2009 pandemic influenza infection.
IL-17-deficient mice ameliorated acute lung injury induced by the BJ501 strain of S-OIV H1N1
The Th-17 hypothesis is the first major revision of the Th-1/Th-2 hypothesis of T cell-mediated tissue damage [24] . IL-17 has been associated with tissue damage in the brain, joints, heart, lungs and intestines, in experimental models [25] [26] [27] . However, the role of IL-17 in lung injury induced by influenza is controversial [28] [29] [30] . Here, the establishment of a suitable mouse model enabled us to directly test whether IL-17 mediates or protects from the acute lung injury induced by 2009 pandemic influenza infection.
To this end, IL-17A-deficient mice were infected with the 2009 pandemic influenza virus BJ501. We found that the survival rates of mice were significantly increased compared with infected wild-type (WT) mice ( Figure  4A ). Body weight losses of > 30% were observed in infected WT control mice, but were not seen in infected IL-17A-deficient mice ( Figure 4B) . Compared with the infected WT control mice, the lung histopathologies in IL-17A-deficient mice were significantly improved, and lung injury scores, as defined by leukocyte infiltration cell counts, were significantly reduced ( Figure  4C) . Moreover, the wet-to-dry lung weight ratios used to measure pulmonary edema in IL-17A-deficient mice were significantly decreased ( Figure 4D) . Notably, the levels of Th-17 mediators and responsive cytokines and chemokines were all significantly reduced in the infected IL-17A-deficient mice compared with infected WT control mice ( Figure 4E ). Altogether, these data indicate that IL-17 plays a critical role in mediating the acute lung injury caused by 2009 pandemic H1N1 influenza infection.
Monoclonal antibodies against IL-17 protected against acute lung injury in S-OIV H1N1-infected mice
Our finding that the IL-17 response to 2009 pandemic H1N1 influenza plays a critical role in mediating acute lung injury not only sheds light on the molecular mechanism of acute lung injury induced by 2009 pandemic H1N1 influenza, but also suggests that inhibition of IL-17A may therapeutically ameliorate the induced acute lung injury. Currently, therapeutic monoclonal antibodies comprise the majority of recombinant proteins used in clinics [31] . To test whether monoclonal antibodies against IL-17A could protect against 2009 pandemic influenza infection, we treated BJ501 virus-infected mice with monoclonal antibodies against human IL-17A. We found that the therapeutic effect of the monoclonal antibody against IL-17A was significant. The survival rates of mice treated with anti-IL-17A monoclonal antibodies were significantly increased compared with isotype control-treated mice ( Figure 5A ), and body weight losses in mice treated with anti-IL-17A monoclonal antibodies were reduced ( Figure 5B ). In addition, lung histopathology alterations and formation of lung edema in the infected mice treated with anti-IL-17A monoclonal antibodies were significantly improved compared with the isotype control-treated mice ( Figure 5C and 5D) . The levels of Th-17 mediators and responsive cytokines and chemokines were also all significantly reduced in the infected mice treated with anti-17 antibodies compared with infected mice treated with isotype-control ( Figure  5E ).
IL-17 could be secreted by many cells, such as Th-17 cells, gamma delta T cells and natural killer cells [32, 33] . Cytokine kinetics of mice BALFs infected with BJ501 virus were assessed. The elevation of both IL-17A and IL-17F were detectable at 12 h of post-infection, suggesting that gamma delta T cells may be the main source of IL-17 elevation (Figure 6A, 6B) .
We also tested whether inhibition of Th-1 mediators provides protection against 2009 pandemic virus infection. Clinically available monoclonal antibodies against TNF-alpha receptor II were injected to mice infected with BJ501, and the survival rates of these monoclonal antibody-treated mice were not improved (Supplementary information, Figure S2A ). Body weight losses of 30% were observed in these mice (Supplementary information, Figure S2B) , and lung tissue wet-to-dry ratios also were not improved, compared with isotype-control-treated mice (Supplementary information, Figure S2C ). This finding is consistent with a previous report that TNFR signaling was dispensable for weight loss in response to PR8 virus infection [29] . In addition, we monitored virus replication in infected lungs of mice treated with monoclonal and isotype control antibodies. No difference in virus replication was observed, indicating that IL-17 may not influence the proliferation of BJ501 influenza (Supplementary information, Figure S3 ). Altogether, these data suggest that therapeutic anti-IL-17A monoclonal antibody treatment may be a useful remedy in the event of a return of the 2009 influenza pandemic.
Discussion
The role of IL-17 was previously investigated in animal models of PR8 influenza infection. The role of IL-17 as a protective cytokine against lethal influenza challenge and its role in mediating the immunopathology of influenza infection have been reported [28, 29] . Hamada et al. [28] claimed that IL-17-secreting CD4 T (Th)-17 and CD8 T (Tc)-17 effector cells were present in the lung following primary challenge with influenza A, and reported that a blocking-antibody treatment against IL-17 increased weight loss and reduced survival rate. In reality, the anti-IL-17 antibody studies were only performed in a heterotypic challenge model. The authors did not study anti-IL-17 in primary influenza infection, in which nearly all of the IL-17 comes from gamma delta T cells [28] . Crowe et al. [29] treated IL-17RA-deficient mice with influenza A, and found that weight loss and survival rates were improved in IL-17RA-deficient mice. Three ligands, IL-17A, IL-17F, and IL-25, have been reported capable of signaling through IL-17RA [34] . Previous report demonstrated that IL-17F and IL-25 played opposing roles of IL-17A in the regulation of lymphopoiethin production in human nasal epithelial cells [35] . Our study found that IL-17F was also elevated in BALF of mice infected with BJ501 live virus ( Figure 6B ). Further studies are necessary to elucidate the roles of IL-17F and IL-25 in the BI501 virus infection. The role of IL-17 is more complicated when bacterial pneumonia is studied in the context of influenza A co-infection. Kudva et al. [30] found that influenza A inhibits the Th-17-mediated host defense against bacterial pneumonia in mice. Although further studies are necessary to elucidate the complex role of IL-17 in PR8 influenza infection, our S-OIV infection studies support the hypothesis that IL-17 mediates acute lung injury in mice. IL-17 has been shown to play critical roles in the immune response and be associated with various models of immune-mediated tissue injury [24, 33] . IL-17 acts as a pro-inflammatory cytokine that induces the expansion and accumulation of neutrophils of the innate immune system and links innate and adaptive immunity [33] . Our mouse model of the BJ501 strain of S-OIV H1N1 showed a cytokine profile similar to that observed in patient serum samples ( Figure 3B ). More studies using the mouse model of BJ501 S-OIV H1N1 infection will be necessary to further elucidate this mechanism.
A therapeutic, fully human monoclonal antibody against IL-17 (mAb AIN457) has been developed by Novartis, and Phase II and Phase III clinical trials for uveitis, Crohn's disease, psoriasis and rheumatoid arthritis are underway [36, 37] . The clinical data for the monoclonal antibody AIN457 and placebo groups support the role of IL-17 in the pathophysiology of inflammatory diseases, including uveitis, psoriasis and rheumatoid arthritis [37] . Our experimental results from the mouse model of S-OIV H1N1 infection suggest that such therapeutic approaches could be useful for patients infected with the 2009 pandemic influenza virus, which will likely be circulating in the winter of 2011/2012.
Materials and Methods
Viruses and reagents
The influenza viruses used in this study were seasonal H1N1, influenza A (H1N1) virus strain A/Beijing/501/2009 (BJ501), influenza A (H1N1) virus strain CA07, and influenza A (H1N1) virus strain A/PR/8/1934 (PR8). Live-virus experiments were performed in Biosafety Level 3 facilities under governmental and institutional guidelines. Viruses were propagated by inoculation into 10-to 11-day-old SPF embryonated fowl eggs via the allantoic route.
Oseltamivir phosphate was purchased from Beijing HuameiHuli Biochem. Isotype-control antibody Mouse IgG2b was purchased from Beijing Protein Innovation, and anti-IL-17 antibody Mouse IgG2b was purchased from Beijing Protein Innovation. 
Mice
Viral pathogenesis in mice
LD50 WT 4-and 6-to 8-week-old B/C and B6 mice were used in this study. Ten mice per group were anesthetized with pentobarbital sodium and intranasally inoculated with 101.5, 102.5, 103.5, 104.5, 105.5 or 106.5 of the 50% tissue culture infectious dosage (TCID50) of the virus or virus dilution buffer (diluent). Survival was monitored daily for 14 days, and the median lethal doses in the mice were calculated.
Survival rate and body weight changes
WT 4-week-old B6 mice were treated intranasally with 105.5 TCID50 of virus or virus diluent. The survival percentages and body weights in each group of ten mice were monitored daily for 14 days. Survival data were analyzed by Kaplan-Meier survival analysis using GraphPad Prism 5 software.
Growth kinetics of the virus in the lung tissue of mice
WT 4-week-old B6 mice were intranasally inoculated with 105.5 TCID50 of virus. Samples of lung tissue were collected at 6, 24, 48, 72, 96, 120, 144 and 168 hours after infection. The titers of viruses in the lung tissue in each group of three mice were determined by plaque assay in MDCK cells.
Histological examination
After being anesthetized with pentobarbital sodium, 4-weekold B6 mice were treated intranasally with 105.5 TCID50 of virus 
Acute pulmonary edema (wet-to-dry ratio)
To assess the extent of acute pulmonary edema, the lung wetto-dry weight ratios were calculated. WT 4-and 6-to-8-week-old B/C and B6 mice were used in this study. Six mice per group were anesthetized with pentobarbital sodium, and intranasally inoculated with 105.5 TCID50 virus or virus diluent. At 5 DPI, the wet weights of the lungs from the mice were measured. The lungs were then heated to 68 °C for 24 hours, and the dry weights of the lungs were recorded, after which the wet-to-dry ratios were calculated.
Cytokine and chemokine measurement
Three WT 4-week-old B6 mice per group were used in this study. For cytokine and chemokine measurements, mouse BALFs were collected after the mice were inoculated with virus or virus diluent for 24 hours. BALFs were processed with the Bio-Plex Mouse Cytokine 23-Plex. Array analysis was performed using the Bio-Plex Protein Array system (Bio-Rad Laboratories).
Antiviral sensitivity of viral infection in mice
WT 4-week-old B6 mice were anesthetized with pentobarbital sodium and were infected intranasally with 105.5 TCID50 of BJ501. Oseltamivir phosphate or placebo was subsequently administered intraperitoneally: (1) oseltamivir phosphate: 10 mg per kg per day, dissolved in 100 µl of phosphate buffered saline and administered daily (starting at 6 hours before virus infection) for 3 days; (2) placebo: 100 µl of phosphate buffered saline, administered daily (starting at 6 hours before virus infection) for 3 days; (3) Oseltamivir phosphate: 10 mg per kg per day, dissolved in 100 µl of phosphate buffered saline and administered daily (starting at 48 hours after virus infection) for 10 days; (4) placebo: 100 µl of phosphate buffered saline, administered daily (starting at 48 hours after virus infection) for 10 days. Survival rate, histology and acute pulmonary edema (wet-to-dry ratio) were measured as described in the viral pathogenesis in mice section.
Pathogenesis of the virus in IL-17
-/-mice WT 4-week-old B6 mice and IL-17 -/-mice (B6 background) were anesthetized with pentobarbital sodium and were intranasally inoculated with 105.5 TCID50 of BJ501 or an equal volume of virus diluent. The survival rate, body weight change, histology, acute pulmonary edema (wet-to-dry ratio), and cytokine and chemokine measurements were performed as described above in the viral pathogenesis in mice section.
Anti-inflammatory sensitivity of viral infection in mice
To test the sensitivity of the viral infection to treatment with anti-IL-17 antibodies and isotype control antibodies, WT 4-week-old B6 mice were anesthetized with pentobarbital sodium and were infected intranasally with 105.5 TCID50 of BJ501. Subsequently, anti-IL-17 antibodies or isotype control antibodies were intravenously administered (50 µg per mouse each day for 3 administrations, starting 1 day before infection): (1) isotype control antibody or (2) anti-IL-17 antibody. Survival rate, body weight change, histology, acute pulmonary edema (wet-to-dry ratio) and cytokine and chemokine measurements were performed as described above in the viral pathogenesis in mice section.
Cytokine and chemokine measurement in patient sera
For cytokine and chemokine measurements, the sera of patients positive for influenza A (H1N1) virus infection were collected. Samples were processed with the Bio-Plex Human Cytokine 25-Plex array. An array analysis was performed using the Bio-Plex Protein Array system (Bio-Rad Laboratories).
Phylogenetic analyses of the HA gene segment
The 
Statistical analyses
All data are shown as means ± SEM. Measurements at single timepoints were analyzed by an ANOVA, and if they demonstrated significance, they were further analyzed by a two-tailed t-test. Time courses were analyzed by a repeated measurement (mixed model) ANOVA with Bonferroni post-t-tests. Survival data were analyzed by a Kaplan-Meier survival analysis. All statistical tests were conducted using GraphPad Prism 5 software. P < 0.05 indicates statistical significance.
Other supplementary Materials and Methods refer to Supplementary information, Data S1.
